Table of Contents
Overview
Definition and Types
Lung cancer is defined as a malignancy that originates in the lungs, typically arising in the airways (bronchi or bronchioles) or the small air sacs (alveoli) of the lungs. It is characterized by the uncontrolled division of damaged cells, leading to the formation of tumors that can impede the proper functioning of the respiratory system and other organs.[3.1] Lung cancer is classified into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Each type includes various subtypes, which are associated with distinct symptoms and treatment options.[2.1] Understanding the stages of both NSCLC and SCLC, which range from stages 1 to 4, is critical in determining the most effective treatment for lung cancer.[1.1] This classification and staging are essential for guiding therapeutic decisions and improving patient outcomes. Understanding the specific types and stages of lung cancer is essential for determining the most effective treatment strategies. Lung cancer is categorized into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).[1.1] Each type exhibits different behaviors, which can influence treatment responses. Furthermore, lung cancer is staged from 1 to 4, and this staging is a critical step in identifying the best treatment options available.[1.1] It is important to note that if lung cancer spreads to another organ, such as the brain, it is still classified as lung cancer, and the behavior of lung cancer cells can vary significantly, affecting their responsiveness to specific treatments.[5.1]Symptoms and Diagnosis
Lung cancer symptoms can vary significantly depending on the stage of the disease. In the early stages, patients may experience subtle signs such as chest pain, chronic cough, breathing difficulties, and weight loss; however, many individuals do not exhibit any symptoms until the cancer has progressed to a more advanced stage due to the limited number of nerve endings in the lungs, which can mask pain and other sensations.[10.1] As the disease advances, particularly in its end stages, common symptoms include severe pain, shortness of breath, and persistent coughing.[9.1] The physiological changes associated with lung cancer, such as ventilation-perfusion (V/Q) mismatch and alterations in lung tissue, can significantly disrupt the balance of oxygenation within the respiratory system, further exacerbating respiratory symptoms.[7.1] For diagnosis, various imaging modalities are employed to detect and stage lung cancer. The chest radiograph is typically the first investigation conducted when lung cancer is suspected.[36.1] Following this, computed tomography (CT) scans with contrast are commonly used, providing detailed three-dimensional images that surpass the capabilities of standard radiography.[34.1] Advanced imaging techniques, including positron emission tomography (PET) and magnetic resonance imaging (MRI), also play crucial roles in the diagnosis and management of lung cancer, offering valuable information for treatment planning.[35.1] Low-dose CT screening has demonstrated a sensitivity of 88.9% and a specificity of 92.6% according to the detection method, making it a valuable tool in lung cancer screening.[37.1] However, when evaluated by the incidence method, the sensitivity of low-dose CT was found to be 79.5%, which is lower than that of traditional chest X-rays, which have a sensitivity of 86.5%.[38.1] Importantly, low-dose CT has been shown to lower mortality rates in high-risk patients compared to X-ray imaging.[39.1] Additionally, scoring systems such as the Brock model can assist in determining the necessity for further imaging, like PET-CT, which is known for its high sensitivity and specificity in diagnosing solitary pulmonary nodules as malignant and in assessing the spread of small cell lung cancer.[39.1]History
Milestones in Lung Cancer Research
The history of lung cancer research is marked by several significant milestones that reflect the evolving understanding of the disease. Initially, lung cancer was considered a rare condition, with early documentation of cases beginning in the mid-19th century. Dr. René Laennec played a pivotal role in the early study of lung cancer, noting that some lung tumors resembled brain tissue, which contributed to the medical community's awareness of the disease.[44.1] In 1912, Isaac Adler published the first literature review on lung cancer, compiling 374 cases from various European registries over the previous 50 years. At that time, many physicians regarded lung cancer as an extremely rare disease, and Adler suggested that it was likely underdiagnosed.[45.1] This marked a critical point in recognizing the need for more comprehensive data on lung cancer incidence. The early 20th century saw a growing suspicion of cigarette smoking as a potential cause of lung cancer, although this was met with skepticism from some medical professionals.[46.1] By the mid-20th century, the perception of lung cancer began to shift dramatically, particularly as smoking became more prevalent. The disease's incidence started to rise exponentially, peaking in the late 1980s, which was closely linked to the massive consumption of cigarettes worldwide.[48.1] As the 21st century approached, lung cancer emerged as a leading cause of cancer-related deaths, highlighting the urgent need for ongoing research and public health initiatives.[47.1] The historical exposure to toxins and the changing patterns of tobacco use underscored the complexity of lung cancer causation and the necessity for continued investigation into its risk factors.[49.1]Causes And Risk Factors
Primary Risk Factors
Smoking tobacco is the predominant risk factor for lung cancer, accounting for approximately 80% of lung cancer deaths. This statistic underscores the significant impact of tobacco use on lung cancer incidence, with many additional cases linked to exposure to secondhand smoke.[95.1] The carcinogenic properties of tobacco smoke are well-documented, as it contains numerous chemicals known to induce mutations in lung cells, leading to cancer development.[100.1] In addition to smoking, genetic factors also contribute to lung cancer risk. Individuals with a family history of lung cancer, particularly those who inherit specific genetic markers on chromosome 6, are at an increased risk of developing the disease.[96.1] This familial risk may be influenced by shared environmental factors, such as smoking and exposure to radon, both of which are known to elevate lung cancer risk.[99.1] The combination of radon exposure and tobacco use significantly heightens the likelihood of developing lung cancer.[100.1] Understanding these risk factors is crucial for identifying high-risk individuals and improving screening and prevention strategies. Environmental factors further contribute to lung cancer risk. Exposure to radon gas, a naturally occurring radioactive gas, is a major risk factor, especially when combined with cigarette smoking, which significantly amplifies the likelihood of developing lung cancer.[100.1] Other environmental contributors include air pollution, which has been linked to increased lung cancer incidence.[99.1]Environmental and Genetic Influences
Lung cancer is a significant global health issue, with many cases attributed to environmental factors, particularly air pollution. Air pollution comprises various components, including particulate matter (PM) and volatile organic compounds (VOCs).[114.1] Particulate matter, especially fine particles with a diameter of 2.5 µm or less (PM2.5), is a prevalent element of air pollution and poses serious health risks, including an increased incidence of lung cancer.[114.1] VOCs, which can be emitted from sources such as industrial operations, automobile emissions, and consumer products, also contribute to lung cancer risk.[116.1] Epidemiological studies have established a clear link between exposure to these pollutants and lung cancer incidence, highlighting air pollution as an under-recognized global health threat associated with an increased risk of various cancers.[120.1] Furthermore, there is a pressing need for policies aimed at reducing pollution levels to mitigate these health risks, as environmental pollution is recognized as a significant risk factor for lung cancer.[121.1] Genetic predispositions play a crucial role in the development of lung cancer, as evidenced by numerous genome-wide association studies (GWAS) that have identified various genetic variants linked to the disease. Specifically, large-scale multinational GWAS have revealed that the 5p15.33, 6p21.33, and 15q25 regions are associated with an increased risk of lung cancer among smokers.[124.1] Additionally, unique genetic regions such as 10q25.2, 6q22.2, and 6p21.32 have been identified as risk factors for lung cancer in individuals who have not smoked.[124.1] Furthermore, interactions between environmental factors, particularly household air pollution (HAP) from solid fuel burning, and genetic susceptibility have been documented, indicating that these interactions can significantly influence lung cancer risk.[123.1] This highlights the multifactorial nature of lung cancer, emphasizing the importance of understanding both genetic and environmental influences in its pathogenesis.In this section:
Global HealthParticulate MatterEnvironmental PollutionGenetic PredispositionsGenome-wide Association Studies
Recent Advancements
Innovations in Treatment
Recent advancements in lung cancer treatment have significantly transformed the landscape of care, particularly through the development of targeted therapies and immunotherapies. The introduction of immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, has provided new avenues for treatment, offering hope for patients with various lung cancer subtypes.[143.1] Additionally, the emergence of small-molecule tyrosine kinase inhibitors has marked a pivotal shift towards precision medicine, which tailors treatment based on the molecular characteristics of a patient's tumor.[158.1] In 2024, notable breakthroughs included the FDA's approval of several new drugs for non-small cell lung cancer (NSCLC), such as durvalumab and the combination of lazertinib with amivantamab-vmjw, which represent significant advancements for patients with specific NSCLC subtypes.[159.1] Furthermore, the approval of repotrectinib as a treatment for advanced lung cancer with ROS1 fusions highlights the ongoing innovation in targeted therapies.[160.1] These developments not only enhance treatment efficacy but also improve survival rates for patients with metastatic NSCLC.[158.1] The integration of genomic profiling and biomarker identification into clinical practice has significantly transformed treatment strategies for patients with advanced non-small cell lung cancer (NSCLC). Genetic testing for mutations such as EGFR, ALK, and ROS1 is now considered a standard of care, reflecting the importance of tailoring treatment based on molecular information specific to a patient's tumor.[156.1] This shift towards precision medicine not only enhances treatment efficacy but also improves patient outcomes by allowing for more personalized approaches.[154.1] Furthermore, the identification of conditions predisposing to lung cancer and the definition of the tumor genetic profile are crucial steps in this process, underscoring the role of comprehensive genomic profiling (CGP) in guiding treatment decisions.[153.1] As the landscape of lung cancer treatment evolves, these advancements highlight the necessity of considering the individual patient’s tumor profile, ultimately fostering a more nuanced approach to oncology that aims to treat the patient as a whole.[147.1]In this section:
Treatment Options
Conventional Therapies
Conventional therapies for lung cancer primarily focus on two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being the most common, accounting for approximately 85 percent of cases.[181.1] Treatment options for NSCLC include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapies.[181.1] It is essential to note that lung cancer treatment decisions are made collaboratively between the patient and their care team, taking into account the specific type of cancer, the stage of the disease, and the patient's treatment goals.[182.1] Each treatment option carries potential risks and benefits, which must be carefully considered in the decision-making process.[182.1] For early-stage lung cancer, specifically stages 1 and 2, the primary treatment is often surgical intervention, which may involve procedures such as lobectomy, segmentectomy, or wedge resection to remove the tumor.[183.1] In instances where the tumor cannot be surgically removed due to its size or location, or if the patient is not healthy enough for surgery, radiation therapy may be utilized as the main treatment, sometimes in conjunction with chemotherapy.[198.1] Additionally, minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both employed for stage 1 non-small cell lung cancer (NSCLC). While MIS is the standard of care for patients with operable disease, selecting patients for SBRT can be complex due to various clinical factors that influence decision-making.[196.1] Overall, treatment options for NSCLC are primarily based on the stage of the cancer, but other factors, such as the patient's overall health and lung function, as well as specific traits of the cancer itself, are also crucial in determining the appropriate therapeutic approach.[199.1] In advanced stages of lung cancer, particularly stage IIIA where surgical options are limited, treatment typically begins with chemotherapy, often combined with radiation therapy, a regimen known as chemoradiation.[199.1] The decision-making process for treatment is collaborative, involving discussions between the patient and their healthcare team to weigh the potential risks and benefits of each option.[203.1]In this section:
Prevention Strategies
Lifestyle Modifications
The most effective lifestyle modification for preventing lung cancer is to refrain from smoking or to quit if currently a smoker. Cigarette smoking is responsible for approximately 80% to 90% of lung cancer deaths in the United States, making it the primary risk factor for the disease.[218.1] Additionally, avoiding exposure to secondhand smoke is crucial, as it significantly increases the risk of lung cancer for non-smokers, with studies indicating a 20% to 30% higher risk for those exposed at home or work.[220.1] Another important preventive measure is to limit exposure to radon, a naturally occurring gas that can seep into homes and is the second leading cause of lung cancer after smoking.[217.1] Testing homes for radon levels and addressing any issues found is recommended to mitigate this risk.[220.1] Furthermore, laws that protect workers from exposure to carcinogenic substances, such as asbestos and arsenic, can also contribute to lowering lung cancer risk.[219.1]Public Health Initiatives
Public health initiatives aimed at preventing lung cancer encompass a variety of strategies, particularly focusing on tobacco control and radon exposure reduction. The American Legacy Foundation's Priority Populations Initiative (PPI) has made significant investments in culturally competent, community-based tobacco control programs, which have been shown to effectively reduce tobacco-related health disparities through coalitions and partnerships among 82 community-based grantees.[221.1] Research indicates that culturally specific tobacco interventions, particularly those delivered through state quitlines, can enhance smoking cessation rates among Black/African American adults, thereby addressing disparities in tobacco use.[222.1] Moreover, culturally tailored tobacco prevention interventions have demonstrated lower initiation rates among adolescents compared to standard conditions, although their effectiveness in increasing cessation rates remains variable.[223.1] Public health strategies that incorporate evidence-based approaches can prevent youth tobacco use, facilitate cessation, and eliminate secondhand smoke exposure, thereby advancing health equity.[224.1] Community interventions, particularly those utilizing social marketing methods, have also proven effective in reducing smoking prevalence. A systematic review highlighted that such initiatives, which combine mass media outreach with community mobilization and environmental changes, significantly impact smoking prevention efforts.[225.1] In addition to community-based initiatives, public health policies play a crucial role in smoking prevention. Measures such as cigarette taxes, smoke-free air laws, and comprehensive tobacco control programs have been identified as effective in reducing smoking prevalence.[244.1] The integration of tobacco dependence treatment into routine healthcare, along with the establishment of barrier-free cessation benefits across various payer types, further enhances the effectiveness of smoking cessation programs.[247.1] Furthermore, the development and enforcement of policies that make tobacco less affordable and protect youth from initiation are essential components of comprehensive tobacco control strategies.[248.1] These initiatives collectively contribute to reducing the incidence of lung cancer by addressing both tobacco use and exposure to harmful substances.In this section:
Current Research Trends
Emerging Therapies and Technologies
Recent advancements in lung cancer research have significantly influenced the development of emerging therapies and technologies, particularly in the realm of non-small cell lung cancer (NSCLC), which accounts for approximately 84% of all lung cancer cases. The landscape of treatment has evolved with the introduction of targeted therapies and immunotherapies, which have been shown to improve patient survival rates, especially in metastatic cases.[280.1] One of the notable breakthroughs in targeted therapy is the use of small-molecule tyrosine kinase inhibitors, which have been developed to specifically target actionable genomic alterations such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements.[281.1] These targeted therapies are tailored to the genetic profile of the tumor, allowing for more personalized treatment approaches that can lead to better outcomes for patients.[282.1] In addition to targeted therapies, immunotherapy has emerged as a promising treatment modality. Recent clinical trials have demonstrated the efficacy of immunotherapeutic agents, such as durvalumab, which has been shown to extend survival in patients with early-stage small cell lung cancer.[267.1] Furthermore, combination therapies that integrate chemotherapy with investigational drugs, like topotecan and berzosertib, have shown potential in shrinking tumors in small cell lung cancer patients.[267.1] The National Cancer Institute (NCI) has been instrumental in advancing research efforts, focusing on the identification of genetic alterations that drive lung cancer growth and the development of new treatment options across all stages of the disease.[264.1] The ongoing ALCHEMIST lung cancer trials are particularly noteworthy, as they aim to analyze tumor tissue from patients with early-stage, completely resected NSCLC for gene mutations, subsequently assigning them to treatment trials that test targeted therapies against these mutations.[267.1] The IASLC's 2023 Molecular Testing for Targeted Therapies in Lung Cancer Atlas provides a comprehensive overview of current and emerging molecular targets, specimen acquisition, available assays, and the reporting and interpretation of molecular testing results from both diagnostic and clinical perspectives.[279.1] This resource is particularly significant as it aligns with the advancements in targeted therapy, including small-molecule tyrosine kinase inhibitors and immunotherapy with immune checkpoint inhibitors, which have collectively ushered in the era of precision medicine for lung cancer treatment.[280.1] These developments are crucial, especially considering that lung cancer remains the leading cause of cancer-related deaths worldwide, and both targeted therapy and immunotherapy have significantly improved survival rates for patients with metastatic non-small cell lung cancer.[280.1]In this section:
References
[1] Lung Cancer Stages 0, 1, 2, 3, 4: Small Cell and Non-Small Cell — Learn about stages 1, 2, 3 and 4 of small cell and non-small cell lung cancer, and why staging is a critical step in determining the best treatment for lung cancer.
[2] Types of Lung Cancer: Common, Rare, Aggressive & More — Lung cancer has two main types, NSCLC and SCLC, each with its own subtypes, symptoms and treatment options. Learn what's common, rare and aggressive.
[3] Lung Cancer: Types, Stages, Symptoms, Diagnosis & Treatment — Giving Careers Search ClevelandClinic.org Find A Doctor Locations & Directions Patients & Visitors Health Library Institutes & Departments Appointments Home/ Health Library/ Diseases & Conditions/ Lung Cancer Advertisement Advertisement Lung Cancer Lung cancer is the third most common cancer in the U.S. It’s caused by harmful cells in your lungs growing unchecked. Lung cancer is a disease caused by uncontrolled cell division in your lungs. Damaged cells dividing uncontrollably create masses, or tumors, of tissue that eventually keep your organs from working properly. Policy Lung cancer is the name for cancers that start in your lungs — usually in the airways (bronchi or bronchioles) or small air sacs (alveoli).
[5] Lung cancer overview — If lung cancer spreads to another organ, such as the brain, it is still considered lung cancer. Lung cancer cells differ in how they behave. This makes them more likely to respond to lung cancer treatment, rather than breast cancer treatment, for example. The most common symptoms of lung cancer are: A cough that does not get better, only worse
[7] Non-invasive Mechanical Ventilation in Lung Cancer: Physiological ... — A cascade of physiological changes can disrupt the delicate balance of oxygenation within the respiratory system in patients with lung cancer. These changes encompass different factors, prominently including ventilation-perfusion ratio (V/Q) mismatch and lung tissue alterations.
[9] How Quickly Does Lung Cancer Progress? - Verywell Health — End Stage Lung Cancer The early stages of lung cancer often have no obvious symptoms. Additional signs common in end stage lung cancer can include: Stages of Lung Cancer The stages of lung cancer include: End Stage Lung Cancer Along with other lung cancer symptoms, people with advanced lung cancer commonly experience pain, shortness of breath, and coughing. Lung cancer often has no symptoms in its early stages and is diagnosed after it has progressed. Lung cancer- non-small cell: stages. How Chemotherapy for Lung Cancer Works Lung Cancer Survival Without Treatment Lung Cancer Blood Tests and Other Screening Tools Lung Cancer Immunotherapy Lung Cancer Liver Metastasis Common and Rare Stage 1 Lung Cancer Symptoms and Complications Myelosuppression: Decreased Bone Marrow Activity Tips for Choosing a Lung Cancer Treatment Center
[10] Early Signs of Lung Cancer and Advanced Symptoms - Verywell Health — In the early stages, lung cancer symptoms may include chest pain, chronic cough, breathing issues, and weight loss. However, there are often no symptoms until the cancer advances. The lack of symptoms may be because the lungs have very few nerve endings, so you do not feel always pain or other sensations in this area.
[34] Current investigative modalities for detecting and staging lung cancers ... — Following chest radiograph, CT scan with contrast is the most common next imaging modality for furthering the diagnosis and staging in patients with suspected lung cancer. CT uses a series of X-rays to produce a three-dimensional (3D) image, presented as cross-sectional slices providing far greater detail than plain film radiography.
[35] Metastatic Lung Cancer - Radiology In Plain English — Metastatic lung cancer is a serious condition, but advanced imaging techniques help detect and manage the disease effectively. CT, PET-CT, MRI, and bone scans provide important information for diagnosis, staging, and treatment planning.
[36] Lung Cancer and Radiological Imaging - PMC - PubMed Central (PMC) — The present expert review aims to describe the use of radiological imaging modalities for the diagnosis of lung cancer. Methods. Some papers were selected from the international literature, by using mainly Pubmed as a source. Results. Chest x-ray (CXR) is the first investigation performed during the workup of suspected lung cancer.
[37] Sensitivity and specificity of lung cancer screening using chest low ... — The present study is the first report on sensitivity and specificity of annual lung cancer screening using low-dose CT and data from a local Cancer Registry. Sensitivity and specificity of low-dose CT screening according to the detection method were 88.9 and 92.6%. The sensitivity estimated by the incidence method resulted in a value of 79.5%.
[38] Sensitivity and specificity of lung cancer screening using chest low ... — Sensitivity of low-dose CT by the incidence method was 79.5%, whereas that of chest X-ray was 86.5%. Lung cancer screening using low-dose CT resulted in higher sensitivity and lower specificity than traditional screening according to the detection method. However, sensitivity by the incidence method was not as high as this.
[39] Current investigative modalities for detecting and staging lung cancers ... — CT lowers the mortality for high-risk patients when compared to X-ray and certain scoring systems, such as the Brock model can guide the need for further imaging, like PET-CT, which has high sensitivity and specificity for diagnosing solitary pulmonary nodules as malignant, as well as for assessing small cell lung cancer spread.
[44] Understanding Lung Cancer History: A Medical Timeline — Introduction to Lung Cancer History. The story of lung cancer is complex and fascinating. Early doctors noticed more people were getting sick with it. At first, lung cancer was rare. But, by the mid-1800s, cases were increasing. Dr. René Laennec was key in the early study of lung cancer. He found that some lung tumors looked like brain tissue.
[45] Chapter 1: History of Lung Cancer - McGraw Hill Medical — In 1912, Isaac Adler published the first literature review about lung cancer. 1 He listed the known 374 cases mentioned in several European registries over the preceding 50 years. Most physicians at the time thought of lung cancer as an extremely rare disease, and Dr. Adler suspected that lung cancer was underdiagnosed.
[46] Historical Perspectives of the Causation of Lung Cancer — The main social processes apparent in analyzing the history of lung cancer causation include social interest connections and power relations as well as concepts of disbelief, oppression, and greed. Although cigarette smoking was suspected as far back as the early 1900s as disease causing, physicians such as Adler and Kellogg, who recognized
[47] Lung cancer | Description, Types, Symptoms & Treatment - Britannica — Lung cancer, disease characterized by uncontrolled growth of cells in the lungs. Lung cancer was first described in the mid-19th century. In the early 20th century it was considered relatively rare, but by the 21st century it had emerged as a leading cause of cancer-related death. ... In countries with a prolonged history of tobacco smoking
[48] Timeline of Lung Cancer | Encyclopedia MDPI — Lung cancer rates start to increase exponentially (peak at 100/100,000 for men in the late 1980s and currently a plateau at 55/100,000 for women) as a consequence massive consumption of cigarettes worldwide. Rates in never smokers remain stable (~10 to 20/100,000). ... "A Short History of Lung Cancer". Toxicological Sciences 64: 4-6. doi:10.
[49] Understanding Lung Cancer History: A Medical Timeline — Prior to the early 20th century, lung cancer was a rare disease. Lung cancer now constitutes a major health crisis, particularly for men. The lifetime probability of developing lung cancer differs by gender in the U.S. The rising incidence of lung cancer necessitates ongoing research and awareness. Historical exposure to toxins highlights the
[95] Lung Cancer Risk Factors | Smoking & Lung Cancer - American Cancer Society — Several risk factors can make you more likely to develop lung cancer. These factors are related to the risk of lung cancer in general. Risk factors you can change Tobacco smoke. Smoking is by far the leading risk factor for lung cancer. About 80% of lung cancer deaths are thought to result from smoking, and this number is probably even higher
[96] Lung cancer causes and risk factors - Cancer Treatment Centers of America — Causes of small cell lung cancer Genetic risk factors. Family history: Anyone previously diagnosed with lung cancer or anyone with a family history of the disease has an increased risk. In particular, people who inherit chromosome 6 are more likely to develop lung cancer. Lifestyle risk factors
[99] Lung Cancer Basics - American Lung Association — Lung cancer is the leading cause of cancer deaths in the U.S. Smoking poses the greatest risk, but there are others such as exposure to radon and air pollution. Screening high-risk individuals has the potential to dramatically improve lung cancer survival rates. There are multiple types of lung cancer.
[100] Lung Cancer Causes & Risk Factors - American Lung Association — * Lung Cancer State of Lung Cancer Report * Lung Cancer Policy & Advocacy Lung Cancer ### Lung Cancer Lung Cancer Research Anyone can get lung cancer. Smoking is the number one cause of lung cancer. Tobacco smoke contains many chemicals that are known to cause lung cancer. Exposure to radon combined with cigarette smoking significantly increases your lung cancer risk. Give for Clean Air & Healthy Lungs Your tax-deductible donation funds lung disease and lung cancer research, new treatments, lung health education, and more. Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more! State of Lung Cancer Report
[114] Air Pollution and Lung Cancer: Contributions of ... - Springer — Air pollution components contain particulate matter (PM) and gases, including volatile organic compounds. Particulate matter is a common component of air pollution and consists of tiny particles suspended in the air [].These particles can be classified based on their size, with particles with a diameter of 2.5 µm or less (PM 2.5) and PM 10 (10 µm or less), also called coarse particles, and
[116] Unlocking the secrets: Volatile Organic Compounds (VOCs) and their ... — Lung cancer (LCs) is still a serious health problem globally, with many incidences attributed to environmental triggers such as Volatile Organic Compounds (VOCs). VOCs are a broad class of compounds that can be released via various sources, including industrial operations, automobile emissions, and indoor air pollution.
[120] Air pollution and its impact on cancer incidence, cancer care and ... — Air pollution is an under-recognised global health threat linked to an increased risk of cancers and is due primarily to the burning of fossil fuels. This review provides a high-level overview of the associations between outdoor and indoor air pollution and cancer risk and outcomes.Outdoor air pollutants are largely due to the burning of fossil fuels from human activities, although there is
[121] Environmental and occupational determinants of lung cancer — There are studies that tell the environmental risk factors for lung cancer and its genetic susceptibility (167,168) but more research is needed. There is an increased risk of lung cancer due to environmental pollution (169-171). Policies to reduce the pollution level should be in priority.
[123] Interactions between household air pollution and GWAS-identified lung ... — Household air pollution (HAP) attributed to solid fuel burning for heating and cooking, is the leading cause of the overall disease burden in Southeast Asia, and is known to contain lung carcinogens. To evaluate the gene-HAP interactions associated with lung cancer in loci independent of smoking, we analyzed data from studies participating in
[124] Lung Cancer Risk, Genetic Variation, and Air Pollution — Large-scale multinational genome-wide association studies (GWAS) of the genetic variation associated with lung cancer initially found that the 5p15.33, 6p21.33, and 15q25 regions were associated with risk of lung cancer among smokers (Amos et al., 2008; Hung et al., 2008). Interestingly, unique regions including 10q25.2, 6q22.2 and 6p21.32 were associated with lung cancer risk in those who had
[143] New advances in lung cancer treatment: Efficacy, safety, and future ... — In recent years, the rise in immune checkpoint inhibitors (ICIs) (such as programmed cell death protein 1 [PD-1] and programmed cell death ligand 1 [PD-L1] inhibitors) and targeted therapies has brought new hope for the treatment of lung cancer. This Special Issue, entitled "Recent Advances in Lung Cancer Research," focuses on the latest
[147] 2021 Breakthroughs in Lung Cancer Treatment - luminwaves.com — "The shift towards more personalized lung cancer treatment strategies fundamentally changes our approach to oncology, allowing us to treat not just the cancer, but the patient as a whole." Overall, these combination strategies are fostering a more nuanced approach to lung cancer treatment, highlighting a shift towards personalized medicine that considers the individual patient’s tumor profile. These studies not only highlight the innovations in lung cancer treatment but also underscore how clinical trials remain a vital component in understanding patient responses to emerging therapies. In essence, the impact of genetic research on lung cancer treatment extends beyond mere statistics; it offers hope through personalization, making care more effective and improving quality of life for patients.
[153] Diagnostic and Predictive Biomarkers in Lung Cancer - PMC — An early diagnosis, the identification of conditions predisposing to lung cancer, and the definition of the tumor genetic profile are crucial steps to improved patient outcomes. In the present special issue, "Diagnostic and Predictive Biomarkers in Lung Cancer", these important topics are covered across fourteen peer-reviewed papers
[154] Biomarker Testing for Guiding Precision Medicine for Patients With Non ... — Precision medicine therapies continue to drive improved outcomes for patients with non-small cell lung cancer (NSCLC). 1 In the context of lung cancer, precision medicine can be defined as tailoring treatment based on molecular information specific to a patient's tumor. The decision to use these therapies relies on predictive biomarkers, which indicate whether a patient's lung cancer is
[156] Utility of comprehensive genomic profiling in directing treatment and ... — Genetic testing for EGFR, ALK, and ROS1 is a standard of care for patients with advanced non-small cell lung cancer (NSCLC) .Recently, with the identification of new targetable drivers and the emergence of effective targeted therapies, broadly applying comprehensive genomic profiling in the clinical care for advanced NSCLC in lieu of the routine testing for classic drivers has been
[158] Recent advances in therapeutic strategies for non-small cell lung cancer — The development of targeted therapy with small-molecule tyrosine kinase inhibitors and immunotherapy with immune checkpoints inhibitors has ushered in the era of precision medicine in treating lung cancer, which remains the leading cause of cancer-related deaths worldwide. Both targeted therapy and immunotherapy have significantly improved the survival of patients with metastatic non-small
[159] FDA Approves New Treatments for Non-Small Cell Lung Cancer — The Food and Drug Administration (FDA) granted approval for durvalumab and the combination of lazertinib with amivantamab-vmjw as innovative treatments for non-small cell lung cancer (NSCLC). These approvals represent a major advancement in the battle against this challenging disease, offering new hope for patients with specific NSCLC subtypes.
[160] Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI — Treatment with repotrectinib can shrink tumors in people with advanced lung cancer whose tumors have ROS1 fusions. FDA approved the drug in 2023 as an initial or second-line treatment for ROS1-positive NSCLC.
[181] Lung Cancer Treatment | Cancer Trends Progress Report — The two main types of lung cancer are small cell lung cancer and non-small cell lung cancer (NSCLC), which is the most common. About 85 percent of lung cancers are NSCLCs. Primary treatment options for people with NSCLC include surgery, radiation therapy, other local treatments, chemotherapy, immunotherapy, and targeted therapies.
[182] What Are the Types of Lung Cancer Treatment? — Lung cancer treatment decisions are made by you and your care team together. All lung cancer treatment options have potential risks and benefits. Your options are based on what type of cancer you have, your stage of the disease and your lung cancer treatment goals.
[183] Lung cancer - World Health Organization (WHO) — Diagnosis
[196] A Decision-Making Model for Selecting Surgery or Radiotherapy for Early ... — Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with operable disease, selecting which patients should be referred for SBRT has been challenging because there are many clinical factors affecting the decision-making process.
[198] Radiation Therapy for Non-Small Cell Lung Cancer — Depending on the stage of the non-small cell lung cancer (NSCLC) and other factors, radiation therapy might be used: As the main treatment (sometimes along with chemotherapy ), especially if the lung tumor can't be removed because of its size or location, if a person isn't healthy enough for surgery, or if a person doesn't want surgery
[199] Non-small Cell Lung Cancer Treatment by Stage — All About Cancer What Is Cancer? All About Cancer All About Cancer What Is Cancer? All About Cancer All About Cancer * Treatment Choices for Non-Small Cell Lung Cancer, by Stage * Treatment Choices for Small Cell Lung Cancer, by Stage Treatment Choices for Non-Small Cell Lung Cancer, by Stage The treatment options for non-small cell lung cancer (NSCLC) are based mainly on the stage (extent) of the cancer, but other factors, such as a person’s overall health and lung function, as well as certain traits of the cancer itself, are also important. For stage IIIA lung cancers that is not able to be surgically removed, treatment usually starts with chemo, often combined with radiation therapy (called chemoradiation). Cancer
[203] Tips on Talking to Your Doctor and Lung Cancer Care Team — Communicate what you know and what you want to know about your lung cancer. Ask your provider to explain things to you in your terms. It can be helpful to repeat back what you hear. ... When you and your doctor work together to discuss your options and decide on a plan, you will better understand and have more confidence in your treatment
[217] Lung Cancer Prevention - Johns Hopkins Medicine — The best prevention for lung cancer is to stop smoking — or never start. ... Limiting exposure to radon is another prevention strategy. Surprisingly, exposure to radon is the second most common cause of lung cancer in the nation, after smoking. Radon comes from the ground and can seep into groundwater and into homes, through cracks in the
[218] Reducing Risk for Lung Cancer | Lung Cancer | CDC - Centers for Disease ... — Cigarette smoking causes about 80% to 90% of lung cancer deaths in the United States. The most important thing you can do to prevent lung cancer is to not start smoking, or, if you smoke, to quit. Avoid secondhand smoke. Smoke from other people's cigarettes, cigars, or pipes is called secondhand smoke. Make your home and car smoke-free.
[219] Lung Cancer Prevention - NCI - National Cancer Institute — Tobacco smoking is the most important risk factor for lung cancer. Studies have shown that smoking low tar or low nicotine cigarettes does not lower the risk of lung cancer. Being exposed to secondhand tobacco smoke is also a risk factor for lung cancer. The risk of lung cancer following radiation therapy is higher in patients who smoke than in nonsmokers. The risk of lung cancer is even higher in people who are exposed and also smoke. Laws that protect workers from being exposed to cancer-causing substances, such as asbestos, arsenic, nickel, and chromium, may help lower their risk of developing lung cancer. Laws that prevent smoking in the workplace help lower the risk of lung cancer caused by secondhand smoke.
[220] Lung Cancer Awareness | Cancer | CDC - Centers for Disease Control and ... — To lower your lung cancer risk, don't smoke, avoid secondhand smoke, and get your home tested for radon. Nearly 9 in 10 lung cancers are caused by smoking cigarettes. People who have never smoked but are exposed to secondhand smoke at home or at work have a 20% to 30% higher risk of getting lung cancer. This video explains what radon is, how it can enter your home and cause lung cancer, and how to fix a radon problem if needed. That is why lung cancer screening is recommended only for adults who are at high risk for developing the disease because of their smoking history and age. Lung cancer screening is not a substitute for quitting smoking.
[221] Engaging Culturally Competent, Community-Based Programs in Reducing ... — The American Legacy Foundation (Legacy) made a substantial investment in capacity building for culturally competent, community-based tobacco control programs through its Priority Populations Initiative (PPI). 6 A conceptual framework was developed to describe the collective contributions of 82 community-based PPI grantees through coalitions and partnerships toward reducing tobacco-related
[222] Culturally Specific Tobacco Intervention Efficacy - NIMHD — The researchers concluded that culturally specific tobacco interventions delivered through state quitlines can increase smoking cessation among Black/African American adults, and that the PTF video intervention has the potential to reduce tobacco-associated disparities that disproportionately burden this population.
[223] A Review of Culturally Targeted/Tailored Tobacco Prevention and ... — Overall, culturally tailored tobacco prevention interventions yielded lower tobacco initiation rates among all adolescents compared with their respective control or standard conditions, but for the most part, culturally tailored tobacco cessation interventions did not yield higher abstinence rates than control/standard-care conditions; the
[224] Public Health Strategies for Tobacco Prevention and Control — Public Health Strategies for Tobacco Prevention and Control | REACH | CDC Putting evidence-based strategies into action can prevent young people from using tobacco products, help people quit using tobacco products, eliminate exposure to secondhand smoke, and advance health equity by eliminating tobacco-related disparities. Increase the number and reach of tobacco-free policies in behavioral health facilities.+ Increase evidence-based health communication interventions to reach groups affected by tobacco-related disparities using culturally and linguistically appropriate protocols, channels, and cessation messages.* Resources for local health departments to reduce tobacco use and exposure to secondhand smoke in their communities. Information on how retail strategies can reduce commercial tobacco use and promote health equity.
[225] Health Promotion Methods for Smoking Prevention and Cessation: A ... — A systematic review by Secker-Walker et al., of community interventions to reduce the prevalence of smoking shows the effectiveness of community-based health promotion initiatives. The project 16 incorporates social marketing method for reducing both illegal sales of tobacco and youth tobacco use showed a significant effect on lowering the smoking prevalence. In a review by Gordon et al., 18 out of 21 studies examined short-term impact (up to 1-year) of social marketing intervention on smoking prevention. Reaching the mass public by social marketing and mass media interventions, reaching the individual by MI, peer education, whilst approaching the community via community mobilization and changing the environment by media advocacy and setting based intervention seems to be an extremely effective method of inducing smoking prevention and cessation.
[244] The Impact of Implementing Tobacco Control Policies: The 2017 Tobacco ... — Cigarette taxes, smoke-free air laws, marketing restrictions, and comprehensive tobacco control programs are each found to play important roles in reducing smoking prevalence. Cessation treatment policies and graphic health warnings also reduce smoking and, when combined with policies that increase quit attempts, can improve quit success.
[247] PDF — Enact laws and health systems policies that expand availability and increase use of effective tobacco cessation interventions. Require a comprehensive barrier-free tobacco cessation benefit across payer types.
[248] PDF — The development, implementation, and enforcement of such policies help make tobacco less a ordable and protect kids by reducing initiation and promoting cessation. This guide provides tobacco control program managers with guidance on the best ways to incorporate evidence-based policy strategies in a comprehensive program.
[264] Advances in Lung Cancer Research - NCI - National Cancer Institute — Credit: National Cancer Institute NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat lung cancer. In particular, scientists have made progress in identifying many different genetic alterations that can drive lung cancer growth. This page highlights some of the latest research in non-small cell lung cancer (NSCLC), the most common form of lung cancer, including clinical advances that may soon translate into improved care, NCI-supported programs that are fueling progress, and research findings from recent studies. Researchers continue to look for new treatment options for all stages of lung cancer.
[267] Lung Cancer Research Articles - NCI — Lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. The immunotherapy drug durvalumab (Imfinzi) can help people with early-stage small cell lung cancer live longer, results from a large clinical trial show. A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations. Combining the chemotherapy drug topotecan and the investigational drug berzosertib shrank tumors in some patients with small cell lung cancer, results from an NCI-supported phase 1 clinical trial show.
[279] IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer — The IASLC's 2023 Molecular Testing for Targeted Therapies in Lung Cancer Atlas is now available The IASLC's latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical
[280] Recent advances in therapeutic strategies for non-small cell lung cancer — The development of targeted therapy with small-molecule tyrosine kinase inhibitors and immunotherapy with immune checkpoints inhibitors has ushered in the era of precision medicine in treating lung cancer, which remains the leading cause of cancer-related deaths worldwide. Both targeted therapy and immunotherapy have significantly improved the survival of patients with metastatic non-small
[281] Targeted therapy for lung cancer: Beyond EGFR and ALK — A recognized subset of patients with non-small cell lung cancer (NSCLC) harbor actionable genomic aberrations that can benefit from targeted therapy. In lung cancer, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are well characterized oncogenic drivers for which the therapeutic use of
[282] Update 2025: Management of Non‑Small-Cell Lung Cancer | Lung - Springer — Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non-small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved patient